# Use of Unidirectional Porous β-Tricalcium Phosphate in the Tibial Tunnel for Anterior Cruciate Ligament Reconstruction: A Case Series

**Authors:** Arata Watanabe, Naoya Kikuchi, Takumi Ichihara, Hiroshi Kumagai, Yu Taniguchi, Yuki Sato, Tomonori Kinugasa, Kotaro Ikeda, Masashi Yamazaki

PMC · DOI: 10.7759/cureus.58366 · 2024-04-16

## TL;DR

This case series explores using a new bone substitute in ACL surgery, showing no complications and successful bone healing after one year.

## Contribution

The first clinical use of unidirectional porous β-tricalcium phosphate in tibial tunnels during ACL reconstruction is reported.

## Key findings

- Nine patients received UDPTCP in tibial tunnels during ACL surgery with no complications.
- Bone remodeling was observed in all patients at one-year follow-up.
- UDPTCP appears to be a safe and reliable bone substitute for tibial tunnel defects.

## Abstract

Bone defects in the tibial tunnel for anterior cruciate ligament (ACL) reconstruction can cause adverse events. The unidirectional porous tricalcium β-phosphate (UDPTCP) has the potential to be used as a filling substitute for bone defects. In this case series, we present the first nine cases in which UDPTCP was used as a bone substitute in the tibial tunnel during ACL reconstruction. The patients comprised six males and three females, with an average age of 32 years (range: 16-50 years). A cylindrical UDPTCP measuring 10 x 20 mm was molded to fit the tibial tunnel and then implanted. At the one-year postoperative follow-up, none of the patients demonstrated any complications, and bone remodeling was observed on radiographs. Therefore, UDPTCP may provide a safe and reliable filling substitute for the tibial tunnel in ACL reconstruction.

## Full-text entities

- **Diseases:** ACL (MESH:D000070598), Bone defects (MESH:D001847)
- **Chemicals:** UDPTCP (-), beta-Tricalcium Phosphate (MESH:C485817)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11097233/full.md

---
Source: https://tomesphere.com/paper/PMC11097233